MannKind Corporation Reports 2015 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Maintains Underweight on MannKind (MNKD) Following Results and Grim Outlook
November 10, 2015 7:01 AM ESTPiper Jaffray analyst Joshua Schimmer reiterated an Underweight rating and $1.50 price target on MannKind (NASDAQ: MNKD) following results.
Schimmer commented, "While cost-cutting measures will help curtail the cash burn, the disappointing launch of Afrezza and increasing net-debt position seem to be making the... More
Leerink Partners' Ominous Sign on MannKind (MNKD)
November 9, 2015 11:29 AM ESTIn addition to poor earnings, MannKind (NASDAQ: MNKD) investors are reacting to the ominous sign from Leerink Partners' Sanofi (NYSE: SNY) analyst Seamus Fernandez.
Fernandez removed Afrezza estimates from their Sanofi 2016 model and... More
MannKind (MNKD) Mentioned Cautiously on Twitter
November 9, 2015 11:26 AM ESTMannKind (NASDAQ: MNKD) was mentioned cautiously on Twitter by theStreet columnist Adam Feuerstein.
. @shaneblackmon $MNKD has to address the bankruptcy question on tonights call. Theyre very close to insolvency. How will co. survive?
Adam Feuerstein (@adamfeuerstein) November 9, 2015
MannKind (MNKD) Misses Q3 EPS by 1c
November 9, 2015 10:18 AM ESTMannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).
For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product... More
